{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:26Z","timestamp":1740106946779,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2014 ID 15373","IG 06\/30\/C\/9"],"award-info":[{"award-number":["IG 2014 ID 15373","IG 06\/30\/C\/9"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00262-018-2286-x","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T22:51:02Z","timestamp":1545087062000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology"],"prefix":"10.1007","volume":"68","author":[{"given":"Anna Maria","family":"Di Giacomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Covre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Giacobini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giorgio","family":"Natali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"1","key":"2286_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7175\/rhc.v5i1.896","volume":"5","author":"M Maio","year":"2014","unstructured":"Maio M, Fonsatti E (2014) The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals. Rev Health Care 5(1):3\u20136. \n                    https:\/\/doi.org\/10.7175\/rhc.v5i1.896","journal-title":"Rev Health Care"},{"key":"2286_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2222-0","author":"M Maio","year":"2018","unstructured":"Maio M, Lofiego MF, Fazio C, Cannito S, Chiarucci C, Giacobini G, Valente M, Tunici P, Covre A, Russo V (2018) Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5\u20137, 2017. Cancer Immunol Immunother. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2222-0","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2286_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 1 26(4):527\u2013534. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.12.7837","journal-title":"J Clin Oncol"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"key":"2286_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","volume":"13","author":"AM Giacomo Di","year":"2012","unstructured":"Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879\u2013886. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(12)70324-8","journal-title":"Lancet Oncol"},{"issue":"10","key":"2286_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 33(10):1191\u20131196. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.56.6018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2286_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/annonc\/mdu577","volume":"26","author":"AM Giacomo Di","year":"2015","unstructured":"Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabr\u00f2 L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M (2015) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 26(4):798\u2013803. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu577","journal-title":"Ann Oncol"},{"issue":"1","key":"2286_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2 373(1):23\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2286_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.tps9090","author":"AM Giacomo Di","year":"2015","unstructured":"Di Giacomo AM (2015) A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.tps9090","journal-title":"J Clin Oncol"},{"issue":"5","key":"2286_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multi centre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"key":"2286_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","author":"HAH Tawbi","year":"2017","unstructured":"Tawbi HAH, Forsyth PAJ, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani N, Gonzalez R, Lao C, Postow M, Atkins MB, Ernstoff M, Puzanov I, Kudchadkar R, Thomas R, Tarhini A, Jiang J, Avila A, Demelo S, Margolin K (2017) Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9507","journal-title":"J Clin Oncol"},{"key":"2286_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.08.004","author":"A Chatterjee","year":"2017","unstructured":"Chatterjee A, Rodger EJ, Eccles MR (2017) Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biolpii. \n                    https:\/\/doi.org\/10.1016\/j.semcancer.2017.08.004","journal-title":"Semin Cancer Biolpii"},{"issue":"18","key":"2286_CR13","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-14-2914","volume":"21","author":"M Maio","year":"2015","unstructured":"Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, Coral S, Sigalotti L (2015) Molecular pathways: at the crossroads of cancer epigenetics and immunotherapy. Clin Cancer Res 21(18):4040\u20134047. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2914","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2286_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pharmthera.2013.12.015","volume":"142","author":"L Sigalotti","year":"2014","unstructured":"Sigalotti L, Fratta E, Coral S, Maio M (2014) Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 142(3):339\u2013350. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.015","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2286_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1053\/j.seminoncol.2015.02.003","volume":"42","author":"A Covre","year":"2015","unstructured":"Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M (2015) Epigenetics meets immune checkpoints. Semin Oncol 42(3):506\u2013513. \n                    https:\/\/doi.org\/10.1053\/j.seminoncol.2015.02.003","journal-title":"Semin Oncol"},{"key":"2286_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS9595","author":"AM Giacomo Di","year":"2016","unstructured":"Di Giacomo AM, Covre A, Taverna P, Coral S, Amato G, Keer HN, Lowder J, Giannarelli D, Azab M, Maio M (2016) A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.TPS9595","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"2286_CR17","doi-asserted-by":"publisher","first-page":"CT059","DOI":"10.1158\/1538-7445.AM2018-CT059","volume":"78","author":"AM Di Giacomo","year":"2018","unstructured":"Di Giacomo AM, Covre A, Finotello F, Rieder D, Sigalotti L, Fazio C, Cutaia O, Bock C, Petitprez F, Lacroix L, Lowder J, Fridman WH, Saut\u00e8s-Fridman C, Trajanoski Z, Maio M (2018) Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial. Cancer Res 78(13 Supplement):CT059. \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT059","journal-title":"Cancer Res"},{"issue":"9","key":"2286_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","volume":"16","author":"JJ Issa","year":"2015","unstructured":"Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O\u2019Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H (2015) Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099\u20131110. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00038-8","journal-title":"Lancet Oncol"},{"issue":"11","key":"2286_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabr\u00f2","year":"2013","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14(11):1104\u20131111. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70381-4","journal-title":"Lancet Oncol"},{"issue":"4","key":"2286_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, Giannarelli D, Di Giacomo AM, Maio M (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3(4):301\u2013309. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(15)00092-2","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2286_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2018","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2018) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18(5):623\u2013630. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30169-9","journal-title":"Lancet Oncol"},{"key":"2286_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P (2018) PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2286_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, Amato G, D\u2019Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M (2018) Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2study. Lancet Respir Med 6(6):451\u2013460. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(18)30151-6","journal-title":"Lancet Respir Med"},{"key":"2286_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2191-3","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Cornelissen R, Aerts J, Maio M (2018) Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. Cancer Immunol Immunother. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2191-3","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2286_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00262-017-2078-8","volume":"67","author":"V Russo","year":"2018","unstructured":"Russo V, Chiarucci C, Lofiego MF, Fazio C, Bertocci E, Cutaia O, Giacobini G, Lazzeri A, Lamboglia A, Altomonte M, Tunici P, Covre A, Maio M (2018) Fourteenth meeting of the network Italiano per la Bioterapia dei Tumori (NIBIT) on cancer bio-immunotherapy, Siena, Italy, October 13\u201315, 2016. Cancer Immunol Immunother 67(6):1023\u20131030. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2078-8","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2286-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:12:18Z","timestamp":1576609938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2286-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2286-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"24 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anna Maria Di Giacomo served on the advisory board of Bristol-Myers Squibb, Incyte, Pierre Fabre, Glaxo Smith Kline and she is a member of the scientific board of directors of the NIBIT Foundation; Ramy Ibrahim is a member of the scientific advisory board of: Arcus, Harpoon, Immunovaccine and ImaginAB;Jaclyn Lyman is a PICI employee; Pier Giorgio Natali is a member of the scientific board of directors of the NIBIT Foundation; Michele Maio served on advisory boards of Bristol-Myers Squibb, Roche-Genentech, Merck Sharp Dohme and AstraZeneca-MedImmune, and he is the president of the NIBIT Foundation. The authors declare that there are no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}